Amino acid for preterm newborns

The main reason for infant mortality worldwide is premature birth. In undeveloped nations, it contributes to premature births and an increase in number of infant and child mortality. The survival rates of high-risk groups have gradually increased in recent years. Preterm births are becoming more common: 11% of births globally take place before 37 weeks of pregnancy. As nutritional care advances in both wealthy and developing nations, the survival rate of preterm infants keeps rising. To promote normal growth and prevent postnatal malnutrition, which may have an impact on long-term neurodevelopmental outcomes, it is crucial to give preterm infants enough protein during the postnatal period. Given that the size, structure, connectivity, and function of the brain develop during infancy, postnatal brain maturation in preterm infants is hindered. There is inconclusive evidence that increased parenteral nutrition amino acid (AA) intake has no impact on mortality. There is limited solid proof to suggest that increasing AA use is associated with a decreased risk of postpartum growth spurts. To find out whether birth weight or gestational age affect nutritional intake of preterm newborns, more research is required. Because the choice to perform life-saving measures is frequently made after the procedure, it is crucial to understand the incidence and severity of adverse events in infants who are extremely preterm. Hence, this article discusses the use of AAs in extremely preterm infants.